The disclosure relates generally to the field of implantable medical devices. Particular embodiments relate to tissue adjustment implants.
It is sometimes necessary or desirable to secure a tissue or portion of a tissue within the body of an animal, such as a human, in a manner that temporarily or permanently adjusts a position or orientation of the tissue or portion of a tissue. For example, in the treatment of Obstructive Sleep Apnea (OSA), it may be desirable to adjust the position of one or more tissues or portions of tissue, such as the soft palate.
OSA is a clinical disorder in which a partial or complete collapse of soft tissue occurs in the airway during sleep. This leads to a blockage of the airway and impaired breathing during sleep. Mild OSA can lead to fatigue, reduced alertness following sleep, and a general reduction in productivity for the affected individual. Severe OSA can lead to sleep deprivation, hypoxemia, and depression.
The art provides various options for the treatment of OSA. Continuous Positive Airway Pressure (CPAP) machines, which supply positive air pressure through a facemask and into the airway during sleep, are used most frequently. The positive air pressure maintains an open airway to prevent apnea and snoring. While these machines are generally considered effective, they are bulky, noisy, and cumbersome to use. Furthermore, use of these machines can be socially awkward for some individuals.
Oral appliances that force the jaw forward to maintain an open airway can also be used. These devices are generally considered to be not as effective as CPAP machines, and can be uncomfortable to use. Furthermore, these devices are frequently ejected from the mouth during sleep, reducing their effectiveness over the entire course of a sleeping period.
Invasive surgical procedures can also be used to treat OSA. Various techniques have been described, including uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and even tracheostomy. Surgical procedures are generally considered to have limited and potentially short-lived effectiveness. Furthermore, many of the procedures require hospitalization and the use of general anesthesia. As a result, these procedures are generally reserved for severe cases of OSA.
The AIRvance™ System from Medtronic, formerly known as the Repose System, provides a surgical-based tongue suspension procedure that can be performed with or without an adjunct hyoid suspension procedure. These suspension procedures require a surgical incision and dissection of the neck below the mandible. Following implantation of one or more necessary bone screws, sutures are lashed around the tongue and/or hyoid bone and secured with surgical knots. While these procedures offer less complicated solutions than the surgical procedures above, they still require surgical intervention and suffer from the drawbacks associated with surgical procedures. Furthermore, over time, the sutures used to suspend the tongue and/or hyoid bone may weaken or even snap, which may limit the effectiveness of the treatment over time. Lastly, the use of sutures in these procedures necessitates the use of specialized knotting and securement techniques to complete the procedure, which adds an additional opportunity for error and failure in the device and the procedure.
Considering the disadvantages of the various available treatment options described above, a need exists for improved devices for adjustment of tissue within the body. Furthermore, a need exists for additional options, including implantable medical devices, for the treatment of OSA.
The following detailed description and the appended drawings describe and illustrate various example embodiments. The description and illustration of these examples are provided to enable one skilled in the art to make and use a tissue adjustment implant. They are not intended to limit the scope of the claims in any manner.
The main body 12 has a lengthwise axis 26 and a transverse axis 28 that orthogonally intersects the lengthwise axis 26 at a longitudinal midpoint 30 disposed on the lengthwise axis 26. A first anchor portion 32 extends along the lengthwise axis 26 of the main body 12 from a point on the lengthwise axis 26 between the longitudinal midpoint 30 and the first end 14 to the first end 14. Similarly, a second anchor portion 34 extends along the lengthwise axis 26 of the main body 12 from a point on the lengthwise axis 26 between the longitudinal midpoint 30 and the second end 16 to the second end 16. A middle portion 36 extends along the lengthwise axis 26 of the main body 12 across the longitudinal midpoint 30 from an end of the first anchor portion 32 to an end of the second anchor portion 34.
The first anchor portion 32 defines a first series of projections 38. Similarly, the second anchor portion 34 defines a second series of projections 40. Each of the first 38 and second 40 series of projections includes a series of projections that extend outwardly from the respective side 18, 20 of the main body 12, away from the longitudinal axis 26. The middle portion 36 is free of outwardly extending projections.
As used herein, the term “projection” refers to an outwardly-directed member or portion of a member that extends away from a surface of another member or another portion of a member. An individual projection can have any suitable shape, including regular and irregular shapes, symmetrical and asymmetrical shapes, and any other suitable shape. The term “series of projections” refers to two or more individual projections. A series of projections includes multiple projections having the same shape, size and or/configurations, a series of projections having different sizes, shapes and configurations, a series of projections spaced at regular intervals, such as a toothed surface, a series of projections spaced at different intervals, and a series of projections spaced at irregular intervals. The illustrated embodiment includes a series of projections extending away from each side 18, 20 of the main body in each series of projections 38, 40. It is understood, though, that any suitable number of projections can extend away from each side 18, 20 of the main body 12 in a series of projections, including one projection, two projections, three projections, or more. Indeed, the number of projections that extend away from a side 18, 20 in a series of projections need only be at least one projection. Furthermore, it is noted that a series of projections can include one or more projections that extend away from only one of the sides 18, 20 of the main body 12 or away from both of the sides 18, 20 of the main body 12.
In the illustrated embodiment, each projection 42 of the first series of projections 38 is substantially triangular in shape and extends away from the longitudinal axis 26 and away from the first end 14 of the main body 12 toward the transverse axis 28. Similarly, each projection 44 of the second series of projections 40 is substantially triangular in shape and extends away from the longitudinal axis 26 and away from the first end 14 of the main body 12 toward the transverse axis 28.
In the illustrated embodiment, a projection 46 of the first series of projections 38 that is farthest from the longitudinal midpoint 30 has a side 48 that is continuous with the first end 14 of the main body 12. Similarly, a projection 50 of the second series of projections 40 that is farthest from the longitudinal midpoint 30 has a side 52 that is continuous with the second end 16 of the main body 12.
Inclusion of the opposing series of projections 38, 40 is considered advantageous at least because each series 38, 40 provides an anchor at an end of the tissue adjustment implant 10 that is opposite an end of the implant that is first inserted into the tissue. Once the tissue adjustment implant 10 is then passed through the tissue, the series of projections at the opposite end are able to engage the tissue and, upon the application of additional force on the tissue engaging implant, such as tension, the position of the tissue can be adjusted, such as by lifting or otherwise moving the tissue, as described more fully below. As an example, described in greater detail below, the tissue adjustment implant can be used to engage and adjust the position of the soft palate of a patient, such as in the treatment of Obstructive Sleep Apnea.
In the illustrated embodiment, the first 22 and second 24 surfaces of the main body 12 are substantially flat. It is noted, though, that it may be advantages to include one or more bumps, projections or other surface modifications on one or both of the surfaces 22, 24. Inclusion of such modifications may improve the handling of the tissue adjustment implant 10 during use.
In this embodiment, the anchor portion 136 defines a first series of projections 138 and a second series of projections 140. Each of the first 138 and second 140 series of projections includes a series of projections that extend outwardly from the respective side 118, 120 of the main body 112, away from the longitudinal axis 126. The first 132 and second 134 end portions are free of outwardly extending projections.
As best illustrated in
In this embodiment, the main body 112 defines a series of openings 164 positioned along the lengthwise axis 126. Each opening of the series of openings 164 extends through the thickness of the main body 112 from the first surface 122 to the second surface 124. As such, each opening defines a passageway that extends through the main body 112. In this embodiment, as best illustrated in
It is noted that any opening in the series of openings 164 can have one or more dimensions that differ from the same dimension or dimensions of another opening in the series of openings 164 while also have one or more dimension that is the same or substantially similar to the same dimension or dimensions of the other openings of the series of openings 164. For example, each opening of the series of openings 164 may have a rectangular shape, with one or more opening having a length and width that differ from the length and width of one or more other rectangular-shaped openings. Also, while the illustrated embodiment includes a series of openings 164, it is noted that any suitable number of openings can be included in a tissue adjustment implant according to a particular embodiment, including zero, one, two, three, or any other suitable number of openings. Inclusion of one or more openings facilitates anchoring of a tissue adjustment implant following implantation.
In this embodiment, a lead 170 is attached to the first end 114 of the main body. The lead 170 provides a leading structure that can be used to form an opening in and/or introduce the tissue adjustment implant into tissue. As such, the lead 170 advantageously includes a portion that can cut into tissue. For example, in the illustrated embodiment, the lead 170 comprises a needle 172 secured to a suture 174 that is attached to the main body 112 near the first end 114. It is noted, though, that any suitable lead structure can be used, including a cutting edge or point that is disposed in the first end of a main body of tissue adjustment implant.
In this embodiment, a plug 180 is disposed on the second end 116 of the main body 112. The plug 180 has a width 182 that is greater than a width 184 of the main body 112 measured from one side 118 to the other 120. In the illustrated embodiment, the plug 180 is a separate member that has been attached to the main body, such as by an adhesive or through mechanical attachment. It is noted, though, that in other embodiments the plug can be integrally formed with the main body.
Inclusion of a plug on an end of the main body facilitates implantation of a tissue adjustment implant because it provides a mechanical stop that impedes further passage of the tissue adjustment implant into the tissue once the plug has reached the point of entry into the tissue, such as an opening through which the remainder of the tissue adjustment implant has been passed. Also, by providing a mechanical stop that impedes further passage of the tissue adjustment implant, the inclusion of a plug facilitates the adjustment function of the tissue adjustment implant. For example, once the plug has reached the point of entry into the tissue, a continued pulling on the tissue adjustment implant, such as a continued pulling on lead attached to the first end of the main body or on the first end of the main body itself, will produce a pulling force on the tissue surrounding the plug at the point of entry. This can be used to lift, move or otherwise adjust the position of the tissue within the body through the application of a simple pulling force on the tissue adjustment implant.
Each of
Any suitable angle, length, shape and configuration can be used for the projections.
It is noted that, while not illustrated in the Figures, any of the tissue adjustment implants illustrated in
If included, the plug can have any suitable size, shape and configuration. Indeed, the plug in a tissue adjustment implant according to a particular embodiment need only have sufficient structure to provide the desired mechanical stop, as described above. Each of
A series of projections 1238 extends from one side 1218 of the main body 1210. The other side 1220 is substantially flat and contains no projections. Thus, in this embodiment, projections extend from only one side of the main body 1210. Also, each of the projections in the series of projections 1238 extends away from the main body 1210, away from the second end 1216. Also, the first 1284 and second 1286 sides of the arrowhead 1280 extend away from the main body 1210 and away from the first end 1214.
The main body 1210 includes a throat portion 1290 that transitions from the width of the base of the arrowhead 1280 to the width of the main body 1210, taken from the first side 1218 to the second side 1220. The inventors have determined that inclusion of the throat portion 1290 provides desirable loading and implantation properties.
The inventors have determined that the inclusion of the arrowhead 1280 and the series of projections 1238 on one side 1218 on the tissue adjustment implant 1200 provides desirable anchoring characteristics while maintaining a low profile structure that facilitates implantation and retention.
The tissue adjustment implant 1200 can be formed as an integral unit that defines the main body, series of projections, first anchor portion, and throat portion. In these embodiments, an integral unit formed as a multi-laminate construct, as described below, is considered advantageous. Alternatively, the tissue adjustment implant 1200 can be formed as separate portions that are attached or otherwise secured to each other. For example, a main body can be formed with the projections, and an anchor portion, such as an anchor portion that defines an arrowhead, can be attached or otherwise secured to an end of the main body to form a tissue adjustment implant.
In this embodiment, the terminal point 1282′ of the arrowhead 1280′ is a rounded point. Also in this embodiment, the first 1284′ and second 1286′ sides of the arrowhead 1280′ are oriented at angle 1288′ with respect to each other. The angle 1288′ of this embodiment is relatively broad, or obtuse, as compared to the angle 1288 in the embodiment illustrated in
In a tissue adjustment implant according to a particular embodiment that includes an anchor portion that defines an arrowhead, the sides of the arrowhead can be oriented with respect to each other at any suitable angle. A skilled artisan will be able to determine a suitable angle for a tissue adjustment implant according to a particular embodiment based on various considerations, including the nature of the tissue within which the tissue adjustment implant is intended to be used, the material forming the tissue adjustment implant, and other considerations. The inventors have determined that an acute angle, such as angle 1288 illustrated in
Examples of suitable angles include an acute angle and an obtuse angle. Acute angles between about 15 degrees and about 90 degrees are also considered suitable. Acute angles between about 35 degrees and about 90 degrees are also considered suitable. Acute angles between about 45 degrees and about 90 degrees are also considered suitable. Acute angles between about 55 degrees and about 90 degrees are also considered suitable. Acute angles between about 65 degrees and about 90 degrees are also considered suitable. Acute angles between about 75 degrees and about 90 degrees are also considered suitable. Acute angles between about 85 degrees and about 90 degrees are also considered suitable. The inventors have determined that an acute angle of about 45 degrees provides a desirable balance between the force required to achieve initial passage of a tissue adjustment implant into tissue during implantation and the degree of anchoring or resistance to reverse movement following implantation. Furthermore, the inventors have determined that an acute angle of 45 degrees provides a desirable balance between the force required to achieve initial passage of a tissue adjustment implant into tissue during implantation and the degree of anchoring or resistance to reverse movement following implantation.
Obtuse angles between about 90 degrees and about 105 degrees are also considered suitable. Obtuse angles between about 90 degrees and about 115 degrees are also considered suitable. Obtuse angles between about 90 degrees and about 125 degrees are also considered suitable. Obtuse angles between about 90 degrees and about 135 degrees are also considered suitable. Obtuse angles between about 90 degrees and about 145 degrees are also considered suitable. Obtuse angles between about 90 degrees and about 155 degrees are also considered suitable. Obtuse angles between about 90 degrees and about 165 degrees are also considered suitable. The inventors have determined that an obtuse angle of about 135 degrees provides a desirable balance between the force required to achieve initial passage of a tissue adjustment implant into tissue during implantation and the degree of anchoring or resistance to reverse movement following implantation. Furthermore, the inventors have determined that an obtuse angle of 135 degrees provides a desirable balance between the force required to achieve initial passage of a tissue adjustment implant into tissue during implantation and the degree of anchoring or resistance to reverse movement following implantation.
A right angle is also considered suitable. The inventors have determined that an angle of about 90 degrees is suitable. Furthermore, the inventors have determined that an angle of 90 degrees is suitable.
As best illustrated in
The tissue adjustment implants can be formed of any suitable material or materials, and a skilled artisan will be able to select an appropriate material or materials for a tissue adjustment implant according to a particular embodiment based on various considerations, including the tissue with which the tissue adjustment implant is intended to be used, the technique by which the tissue adjustment implant will be implanted, and other considerations. Both synthetic and natural materials are considered suitable. Examples of suitable synthetic materials include polymeric materials, such as polyethylene, polypropylene and other flexible polymeric materials. Examples of suitable natural materials include tissue and tissue-derived materials. The inventors have determined that tissue adjustment implants formed of bioremodelable materials are particularly well-suited for implantation within and adjustment of various tissues in human and other animals at least because of the ability of such materials to remodel and become incorporated into adjacent tissues over time. These materials can provide a scaffold onto which cellular in-growth can occur, eventually allowing the material to remodel into a structure of host cells, which aids in the effectiveness of the tissue adjustment implant as a long-term support of the tissue being secured.
Particular advantage can be provided by tissue adjustment implants that incorporate a remodelable collagenous material. Such remodelable collagenous materials, whether reconstituted or naturally-derived, can be provided, for example, by collagenous materials isolated from a warm-blooded vertebrate, especially a mammal. Such isolated collagenous material can be processed so as to have remodelable, angiogenic properties and promote cellular invasion and ingrowth. Remodelable materials may be used in this context to stimulate ingrowth of adjacent tissues into an implanted construct such that the remodelable material gradually breaks down and becomes replaced by new patient tissue so as to generate a new, remodeled tissue structure. Such materials are considered suitable for use in the main body, projections, and plug portions of tissue adjustment implants.
Suitable remodelable materials can be provided by collagenous extracellular matrix (ECM) materials possessing biotropic properties. For example, suitable collagenous materials include ECM materials such as those comprising submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane layers, including liver basement membrane. Suitable submucosa materials for these purposes include, for instance, intestinal submucosa including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa. Collagenous matrices comprising submucosa (potentially along with other associated tissues) useful in the present invention can be obtained by harvesting such tissue sources and delaminating the submucosa-containing matrix from smooth muscle layers, mucosal layers, and/or other layers occurring in the tissue source. For additional information as to some of the materials useful in the tissue adjustment implants, and their isolation and treatment, reference can be made, for example, to U.S. Pat. Nos. 4,902,508, 5,554,389, 5,993,844, 6,206,931, and 6,099,567.
Remodelable ECM tissue materials harvested as intact sheets from a mammalian source and processed to remove cellular debris advantageously retain at least a portion of and potentially all of the native collagen microarchitecture of the source extracellular matrix. This matrix of collagen fibers provides a scaffold to facilitate and support tissue ingrowth, particularly in bioactive ECM implant materials, such as porcine small intestinal submucosa or SIS (Surgisis® Biodesign™, Cook Medical, Bloomington Ind.), that are processed to retain an effective level of growth factors and other bioactive constituents from the source tissue. In this regard, when a tissue adjustment implant incorporates this sort of material, cells will invade the remodelable material upon implantation eventually leading to the generation of a newly-remodeled, functional tissue structure.
Submucosa-containing or other ECM tissue used in the tissue adjustment implants is preferably highly purified, for example, as described in U.S. Pat. No. 6,206,931 to Cook et al. Thus, preferred ECM material will exhibit an endotoxin level of less than about 12 endotoxin units (EU) per gram, more preferably less than about 5 EU per gram, and most preferably less than about 1 EU per gram. As additional preferences, the submucosa or other ECM material may have a bioburden of less than about 1 colony forming units (CFU) per gram, more preferably less than about 0.5 CFU per gram. Fungus levels are desirably similarly low, for example less than about 1 CFU per gram, more preferably less than about 0.5 CFU per gram. Nucleic acid levels are preferably less than about 5 μg/mg, more preferably less than about 2 μg/mg, and virus levels are preferably less than about 50 plaque forming units (PFU) per gram, more preferably less than about 5 PFU per gram. These and additional properties of submucosa or other ECM tissue taught in U.S. Pat. No. 6,206,931 may be characteristic of any ECM tissue used in the inventive tissue adjustment implants.
A typical layer thickness for an as-isolated submucosa or other ECM tissue layer used in the invention ranges from about 50 to about 250 microns when fully hydrated, more typically from about 50 to about 200 microns when fully hydrated, although isolated layers having other thicknesses may also be obtained and used. These layer thicknesses may vary with the type and age of the animal used as the tissue source. As well, these layer thicknesses may vary with the source of the tissue obtained from the animal source. In a dry state, a typical layer thickness for an as-isolated submucosa or other ECM tissue layer used in the invention ranges from about 30 to about 160 microns when fully dry, more typically from about 30 to about 130 microns when fully dry.
Suitable bioactive agents may include one or more bioactive agents native to the source of the ECM tissue material. For example, a submucosa or other remodelable ECM tissue material may retain one or more growth factors such as but not limited to basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), cartilage derived growth factor (CDGF), and/or platelet derived growth factor (PDGF). As well, submucosa or other ECM materials when used in the invention may retain other native bioactive agents such as but not limited to proteins, glycoproteins, proteoglycans, and glycosaminoglycans. For example, ECM materials may include heparin, heparin sulfate, hyaluronic acid, fibronectin, cytokines, and the like. Thus, generally speaking, a submucosa or other ECM material may retain one or more bioactive components that induce, directly or indirectly, a cellular response such as a change in cell morphology, proliferation, growth, protein or gene expression.
Submucosa-containing or other ECM materials used in a tissue adjustment implant can be derived from any suitable organ or other tissue source, usually sources containing connective tissues. The ECM materials processed for use in the inventive tissue adjustment implants will typically include abundant collagen, most commonly being constituted at least about 80% by weight collagen on a dry weight basis. Such naturally-derived ECM materials will for the most part include collagen fibers that are non-randomly oriented, for instance occurring as generally uniaxial or multi-axial but regularly oriented fibers. When processed to retain native bioactive factors, the ECM material can retain these factors interspersed as solids between, upon and/or within the collagen fibers. Particularly desirable naturally-derived ECM materials for use in the invention will include significant amounts of such interspersed, non-collagenous solids that are readily ascertainable under light microscopic examination with appropriate staining. Such non-collagenous solids can constitute a significant percentage of the dry weight of the ECM material in certain inventive embodiments, for example at least about 1%, at least about 3%, and at least about 5% by weight in various embodiments of the invention.
The submucosa-containing or other ECM material used in the inventive tissue adjustment implants may also exhibit an angiogenic character and thus be effective to induce angiogenesis in a host engrafted with the material. In this regard, angiogenesis is the process through which the body makes new blood vessels to generate increased blood supply to tissues. Thus, angiogenic materials, when contacted with host tissues, promote or encourage the formation of new blood vessels into the materials. Methods for measuring in vivo angiogenesis in response to biomaterial implantation have recently been developed. For example, one such method uses a subcutaneous implant model to determine the angiogenic character of a material. See, C. Heeschen et al., Nature Medicine 7 (2001), No. 7, 833-839. When combined with a fluorescence microangiography technique, this model can provide both quantitative and qualitative measures of angiogenesis into biomaterials. C. Johnson et al., Circulation Research 94 (2004), No. 2, 262-268.
Further, in addition or as an alternative to the inclusion of such native bioactive components, non-native bioactive components such as those synthetically produced by recombinant technology or other methods (e.g., genetic material such as DNA), may be incorporated into an ECM material used in an inventive tissue adjustment implant. These non-native bioactive components may be naturally-derived or recombinantly produced proteins that correspond to those natively occurring in an ECM tissue, but perhaps of a different species. These non-native bioactive components may also be drug substances. Illustrative drug substances that may be added to materials include, for example, anti-clotting agents, e.g. heparin, antibiotics, anti-inflammatory agents, thrombus-promoting substances such as blood clotting factors, e.g., thrombin, fibrinogen, and the like, and anti-proliferative agents, e.g. taxol derivatives such as paclitaxel. Such non-native bioactive components can be incorporated into and/or onto ECM material in any suitable manner, for example, by surface treatment (e.g., spraying) and/or impregnation (e.g., soaking), to name a few. Also, these substances may be applied to the ECM material in a premanufacturing step, immediately prior to the procedure (e.g., by soaking the material in a solution containing a suitable antibiotic such as cefazolin), or during or after engraftment of the material in the patient.
Inventive devices can incorporate xenograft material (i.e., cross-species material, such as tissue material from a non-human donor to a human recipient), allograft material (i.e., interspecies material, with tissue material from a donor of the same species as the recipient), and/or autograft material (i.e., where the donor and the recipient are the same individual). Further, any exogenous bioactive substances incorporated into an ECM material may be from the same species of animal from which the ECM material was derived (e.g. autologous or allogeneic relative to the ECM material) or may be from a different species from the ECM material source (xenogeneic relative to the ECM material). In certain embodiments, ECM material will be xenogeneic relative to the patient receiving the graft, and any added exogenous material(s) will be from the same species (e.g. autologous or allogeneic) as the patient receiving the graft. Illustratively, human patients may be treated with xenogeneic ECM materials (e.g. porcine-, bovine- or ovine-derived) that have been modified with exogenous human material(s) as described herein, those exogenous materials being naturally derived and/or recombinantly produced.
The inventors have determined that SIS is particularly well-suited for use in the tissue adjustment implant devices described herein at least because of its well-characterized nature and ready availability. Furthermore, the inventors have determined that vacuum-pressed SIS provides a particularly advantageous material from which to form tissue adjustment implant devices that include one or more pluralities of projections, such as the tissue adjustment implants described and illustrated herein. Lyophilized SIS can also be used, and may be advantageous for tissue adjustment implants in which a relatively quicker remodeling time is desired. Radiopaque SIS can also be used, and may be advantageous for tissue adjustment implants for which enhanced visualization characteristics are desired.
The inventors have determined that a tissue adjustment implant having a main body formed of multiple layers laminated together provides a particularly advantageous structure. Thus, the main body can comprise a multilaminate construct. In these embodiments, any suitable number of layers can be used, and a skilled artisan will be able to select an appropriate number of layers for a particular tissue adjustment implant based on various considerations, including the intended use of the tissue adjustment implant and nature of the tissue intended to be supported by the tissue adjustment implant. The inventors have determined that a tissue adjustment implant having a main body formed of between 4 and 12 layers of an ECM material, such as SIS, provides a particularly advantageous structure for tissue adjustment implants intended for use in supporting the soft palate of a patient, such as in methods of treating Obstructive Sleep Apnea (OSA). A main body formed of between 6 and 10 layers of an ECM material, such as SIS, is also considered particularly advantageous. A main body formed of 8 layers of an ECM material, such as SIS, is also considered particularly advantageous. A main body formed of up to 60 layers of an ECM material, such as SIS, is also considered particularly advantageous. In these embodiments, the layers can be assembled together in any suitable manner and using any suitable technique or process. For multilaminate SIS constructs, the inventors have determined that vacuum-pressing of multiple layers of SIS provides a suitable laminate structure for use as a tissue adjustment implant as described herein. The layers in the multilaminate construct can be vacuum-pressed prior to assembly into the multilaminate construct. Alternatively, the multilaminate construct can be vacuum-pressed after assembly of the layers. Also alternatively, the layers can be vacuum-pressed prior to assembly and the assembly can be vacuum-pressed after assembly. The inventors have determined that use of vacuum-pressed SIS provides desirable durability and profile characteristics. When using a vacuum-pressed layers of an ECM material, such as SIS, any suitable number of vacuum-pressed layers can be used. The inventors have determined that a tissue adjustment implant having a main body formed of between 4 and 60 layers provides a particularly advantageous structure for tissue adjustment implants intended for use in supporting the soft palate of a patient, such as in methods of treating OSA. A main body formed of between 10 and 50 layers is also considered particularly advantageous. A main body formed of between 20 and 40 layers is also considered particularly advantageous. A main body formed of between 25 and 35 layers is also considered particularly advantageous. A main body formed of about 30 layers is also considered particularly advantageous. The inventors have determined that a tissue adjustment implant comprising a multilaminate construct comprised of 30 layers of vacuum-pressed SIS provides a suitable structure for use in methods of treating OSA.
The inventors have determined that a hybrid structure may provide a desirable balance between desired overall rigidity for the tissue adjustment implant and relative remodeling time. In this embodiment, a middle portion of the tissue adjustment implant is formed of lyophilized SIS, which provides a relatively quicker remodeling time, and the perimeter sections, including the ribbed portions, are formed of vacuum-pressed SIS, which provides a relatively high degree of overall rigidity. The middle portion in this embodiment is expected to remodel relatively quickly following implantation, enhancing the securement of the tissue adjustment implant. An opposite structure is also considered suitable and may be advantageous in certain circumstances.
A hybrid structure in which a mesh is embedded inside an SIS or other composition or between layers of SIS or of other material is also considered suitable. For example, a polymeric mesh, such as a mesh formed of polypropylene, can be disposed between layers of SIS during formation of the tissue adjustment implant. In these embodiments, the polymeric mesh will remain in the body following completion of remodeling by the SIS, which may enhance the overall anchoring of the supported tissue over time. A bioabsorable mesh, such as a mesh formed of polyglycolic acid or other bioabsorbable material, can also be included in the tissue adjustment implant in this manner and may be advantageous where supplemental support is desired that lasts beyond the remodeling time for the SIS, but that does not have the permanency associated with a polypropylene or other polymeric mesh. Examples of suitable structural arrangements of polymer and remodelable layers can be found in United States Patent Application Publication No. 2011/0166673 to Patel et al., for QUILTED IMPLANTABLE GRAFT, the entire contents of which are hereby incorporated into this disclosure.
A tissue adjustment implant, or portions thereof, can also be coated with particular materials to provide a desired property or properties. For example, the inventors have determined that coating a tissue adjustment implant with poly(lactic-co-glycolic acid) (PLGA) provides a desirable stiffening effect to the implant while also providing an agent that promotes an inflammatory response in tissue within which the tissue adjustment implant has been placed. In tissue adjustment implants that comprise a multilaminate construct, as describe above, a coating can be applied between layers during fabrication. For example, PLGA can be applied to or embedded within one, two, a plurality of, or all of the layers when making a main body that comprise a multilaminate construct.
The tissue adjustment implants are implanted by forming an opening in a target tissue, passing the first end of the tissue adjustment implant through the opening and into the tissue until the plug contacts the tissue surrounding the opening. If desired, additional pulling force can be applied to the first end to lift or otherwise adjust the position of the tissue through interaction with the plug. Once a desired position is achieved, a portion of the tissue adjustment implant, such as a portion near the first end of the tissue adjustment implant, can be sutured to the tissue. This is beneficial for maintaining the adjusted position of the tissue.
After passing the first end of the tissue adjustment implant through the opening in the tissue and into the tissue, the first end of the tissue adjustment implant, or a lead attached to it, can be manipulated to exit the tissue, either through an existing opening or by forming an opening, at a point at a distance from the opening through with the tissue adjustment implant entered the tissue. This is particularly advantageous for tissue adjustment implants that include a lead, such as a needle and suture attached to a first end of the tissue adjustment implant. Also, if desired, the tissue adjustment implant can be trimmed of excess main body such that the remainder of the tissue adjustment implant is flush or substantially flush with the opening through which the tissue adjustment implant exits the tissue. If this is performed, it is advantageously performed after the tissue adjustment implant is secured to the tissue, if performed, such that any desired adjusted position of the tissue is maintained after the trimming is completed.
The tissue adjustment implants are particularly well-suited for adjusting the position of the soft palate of a patient, such as a human being. Such an adjustment may be beneficial in the treatment of Obstructive Sleep Apnea (OSA).
Those with ordinary skill in the art will appreciate that various modifications and alternatives for the described and illustrated embodiments can be developed in light of the overall teachings of the disclosure. Accordingly, the particular arrangements disclosed are intended to be illustrative only and not limiting as to the scope of the invention, which is to be given the full breadth of the appended claims and any and all equivalents thereof.
This application claims the benefit of U.S. Provisional Application No. 61/861,089, filed on Aug. 1, 2013. The disclosure of this related application is hereby incorporated into this disclosure in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4024859 | Slepyan et al. | May 1977 | A |
4064873 | Swenson | Dec 1977 | A |
4608972 | Small | Sep 1986 | A |
4917604 | Small | Apr 1990 | A |
5674191 | Edwards et al. | Oct 1997 | A |
5988171 | Sohn et al. | Nov 1999 | A |
6159208 | Hovda et al. | Dec 2000 | A |
6161541 | Woodson | Dec 2000 | A |
6397841 | Kenyon et al. | Jun 2002 | B1 |
6408851 | Karell | Jun 2002 | B1 |
6513530 | Knudson et al. | Feb 2003 | B2 |
6513531 | Knudson et al. | Feb 2003 | B2 |
6523541 | Knudson et al. | Feb 2003 | B2 |
6895963 | Martin et al. | May 2005 | B1 |
6910483 | Daly et al. | Jun 2005 | B2 |
6955172 | Nelson et al. | Oct 2005 | B2 |
6974419 | Voss et al. | Dec 2005 | B1 |
7004941 | Tvinnereim et al. | Feb 2006 | B2 |
7047979 | Conrad et al. | May 2006 | B2 |
7063089 | Knudson et al. | Jun 2006 | B2 |
7073505 | Nelson et al. | Jul 2006 | B2 |
7090672 | Underwood et al. | Aug 2006 | B2 |
7128069 | Farrugia et al. | Oct 2006 | B2 |
7168429 | Matthews et al. | Jan 2007 | B2 |
7188627 | Nelson et al. | Mar 2007 | B2 |
7213599 | Conrad et al. | May 2007 | B2 |
7216647 | Lang et al. | May 2007 | B2 |
7255109 | Knudson et al. | Aug 2007 | B2 |
7291112 | Martin et al. | Nov 2007 | B2 |
7337778 | Martin et al. | Mar 2008 | B2 |
7337781 | Vassallo | Mar 2008 | B2 |
7360542 | Nelson et al. | Apr 2008 | B2 |
7363926 | Pflueger et al. | Apr 2008 | B2 |
7387634 | Benderev | Jun 2008 | B2 |
7401611 | Conrad et al. | Jul 2008 | B2 |
7491200 | Underwood | Feb 2009 | B2 |
7607439 | Li | Oct 2009 | B2 |
7644714 | Atkinson et al. | Jan 2010 | B2 |
7658192 | Harrington | Feb 2010 | B2 |
7669603 | Knudson et al. | Mar 2010 | B2 |
7673635 | Conrad et al. | Mar 2010 | B2 |
7680538 | Durand et al. | Mar 2010 | B2 |
7703460 | Conrad et al. | Apr 2010 | B2 |
7813812 | Kieval et al. | Oct 2010 | B2 |
7827038 | Richard et al. | Nov 2010 | B2 |
7827988 | Matthews et al. | Nov 2010 | B2 |
7845357 | Buscemi et al. | Dec 2010 | B2 |
7856980 | Lang et al. | Dec 2010 | B2 |
7874291 | Ging et al. | Jan 2011 | B2 |
7884101 | Teegarden et al. | Feb 2011 | B2 |
7909037 | Hegde et al. | Mar 2011 | B2 |
7909038 | Hegde et al. | Mar 2011 | B2 |
7921850 | Nelson et al. | Apr 2011 | B2 |
7934506 | Woodson et al. | May 2011 | B2 |
7935065 | Martin et al. | May 2011 | B2 |
7938114 | Matthews et al. | May 2011 | B2 |
7949400 | Kieval et al. | May 2011 | B2 |
7954494 | Connor | Jun 2011 | B1 |
7955267 | Voss et al. | Jun 2011 | B2 |
7959554 | McAlexander et al. | Jun 2011 | B2 |
7975700 | Frazier et al. | Jul 2011 | B2 |
7976471 | Martin et al. | Jul 2011 | B2 |
7980248 | Hegde et al. | Jul 2011 | B2 |
7992564 | Doshi et al. | Aug 2011 | B2 |
7992566 | Pflueger et al. | Aug 2011 | B2 |
7992567 | Hirotsuka et al. | Aug 2011 | B2 |
7997266 | Frazier et al. | Aug 2011 | B2 |
7997267 | Ging et al. | Aug 2011 | B2 |
8020560 | Paraschac et al. | Sep 2011 | B2 |
8074655 | Sanders | Dec 2011 | B2 |
8096303 | Dineen et al. | Jan 2012 | B2 |
8167787 | Gillis | May 2012 | B2 |
8186355 | van der Burg et al. | May 2012 | B2 |
8220466 | Frazier et al. | Jul 2012 | B2 |
8220467 | Sanders | Jul 2012 | B2 |
8327854 | Gillis et al. | Dec 2012 | B2 |
8460322 | van der Burg et al. | Jun 2013 | B2 |
8932325 | Stanley | Jan 2015 | B2 |
8936616 | Nelson | Jan 2015 | B2 |
20010050085 | Knudson et al. | Dec 2001 | A1 |
20030111079 | Matthews et al. | Jun 2003 | A1 |
20030140925 | Sapienza et al. | Jul 2003 | A1 |
20030168064 | Daly et al. | Sep 2003 | A1 |
20040028676 | Klein et al. | Feb 2004 | A1 |
20040112387 | Lang et al. | Jun 2004 | A1 |
20040153127 | Gordon et al. | Aug 2004 | A1 |
20040187870 | Matthews et al. | Sep 2004 | A1 |
20050005937 | Farrugia et al. | Jan 2005 | A1 |
20050098184 | Conrad et al. | May 2005 | A1 |
20050103339 | Daly et al. | May 2005 | A1 |
20050126563 | van der Burg et al. | Jun 2005 | A1 |
20050178384 | Martin et al. | Aug 2005 | A1 |
20050217673 | Daly et al. | Oct 2005 | A1 |
20050267547 | Knudson et al. | Dec 2005 | A1 |
20050279365 | Armijo et al. | Dec 2005 | A1 |
20060000475 | Matthews et al. | Jan 2006 | A1 |
20060070626 | Frazier et al. | Apr 2006 | A1 |
20060150986 | Roue et al. | Jul 2006 | A1 |
20060207612 | Jackson et al. | Sep 2006 | A1 |
20060235877 | Richard et al. | Oct 2006 | A1 |
20070132117 | Truitt et al. | Jun 2007 | A1 |
20070134085 | Daly et al. | Jun 2007 | A1 |
20070144539 | van der Burg et al. | Jun 2007 | A1 |
20070157928 | Pujol et al. | Jul 2007 | A1 |
20070157934 | Lang et al. | Jul 2007 | A1 |
20070207994 | Teegarden et al. | Sep 2007 | A1 |
20070209664 | Paraschac et al. | Sep 2007 | A1 |
20070209665 | Gillis et al. | Sep 2007 | A1 |
20070244086 | Teegarden et al. | Oct 2007 | A1 |
20070256693 | Paraschac et al. | Nov 2007 | A1 |
20070287923 | Adkins et al. | Dec 2007 | A1 |
20080023012 | Dineen et al. | Jan 2008 | A1 |
20080027560 | Jackson et al. | Jan 2008 | A1 |
20080041382 | Matthews et al. | Feb 2008 | A1 |
20080041383 | Matthews et al. | Feb 2008 | A1 |
20080045813 | Phuah et al. | Feb 2008 | A1 |
20080053461 | Hirotsuka et al. | Mar 2008 | A1 |
20080058584 | Hirotsuka et al. | Mar 2008 | A1 |
20080066753 | Martin et al. | Mar 2008 | A1 |
20080066765 | Paraschac et al. | Mar 2008 | A1 |
20080066769 | Dineen et al. | Mar 2008 | A1 |
20080097380 | Li | Apr 2008 | A1 |
20080099019 | Martin et al. | May 2008 | A1 |
20080194953 | Kerber | Aug 2008 | A1 |
20080208265 | Frazier et al. | Aug 2008 | A1 |
20080251071 | Armitstead et al. | Oct 2008 | A1 |
20090044814 | Iancea et al. | Feb 2009 | A1 |
20090053306 | Agarwal et al. | Feb 2009 | A1 |
20090060905 | Martin et al. | Mar 2009 | A1 |
20090099471 | Broadley et al. | Apr 2009 | A1 |
20090131923 | Connors et al. | May 2009 | A1 |
20100004264 | Xiong et al. | Jan 2010 | A1 |
20100010061 | Cooper et al. | Jan 2010 | A1 |
20100016694 | Martin et al. | Jan 2010 | A1 |
20100028026 | Inami et al. | Feb 2010 | A1 |
20100106246 | Rousseau et al. | Apr 2010 | A1 |
20100108066 | Martin et al. | May 2010 | A1 |
20100108077 | Lindh | May 2010 | A1 |
20100132719 | Jacobs | Jun 2010 | A1 |
20100144701 | Cooper et al. | Jun 2010 | A1 |
20100234946 | Rousseau | Sep 2010 | A1 |
20100300458 | Stubbs et al. | Dec 2010 | A1 |
20110056498 | Lang et al. | Mar 2011 | A1 |
20110094520 | Mikhailenok et al. | Apr 2011 | A1 |
20110100376 | Rousseau | May 2011 | A1 |
20110100378 | Rousseau | May 2011 | A1 |
20110130249 | Mikhailenok et al. | Jun 2011 | A1 |
20110166673 | Patel et al. | Jul 2011 | A1 |
20110183928 | Thede et al. | Jul 2011 | A1 |
20110226264 | Friedman | Sep 2011 | A1 |
20110245850 | van der Burg et al. | Oct 2011 | A1 |
20110308530 | Gillis et al. | Dec 2011 | A1 |
20130056009 | Mohan et al. | Mar 2013 | A1 |
20130085546 | Bolea et al. | Apr 2013 | A1 |
20130180528 | Zhou et al. | Jul 2013 | A1 |
20130213409 | Podmore et al. | Aug 2013 | A1 |
20140102460 | Catalano | Apr 2014 | A1 |
Number | Date | Country |
---|---|---|
WO 0145765 | Jun 2001 | WO |
2007149469 | Dec 2007 | WO |
2007149469 | Dec 2007 | WO |
2009140197 | Nov 2009 | WO |
2010045546 | Apr 2010 | WO |
2010051195 | May 2010 | WO |
2011068952 | Jun 2011 | WO |
2011068952 | Jun 2011 | WO |
2011123714 | Oct 2011 | WO |
2013010169 | Jan 2013 | WO |
2013010169 | Jan 2013 | WO |
Entry |
---|
International Searching Authority, International Search Report and Written Opinion for International application No. PCT/US2014/049341, dated Nov. 19, 2014, pp. 1-11. |
International Searching Authority, International Search Report and the Written Opinion, for International Application No. PCT/US2012/046923, dated Nov. 2, 2012, p. 1-18. |
File history of U.S. Appl. No. 08/883,220, now U.S. Pat. No. 5,988,171, as of Nov. 21, 2013, filed Jun. 26, 1997. First Named Inventor, Ze'ev Sohn. Title, Methods and Devices for the Treatment of Airway Obstruction, Sleep Apnea and Snoring. |
File history of U.S. Appl. No. 10/877,003, now U.S. Pat. No. 7,213,599, as of Nov. 21, 2013, filed Jun. 24, 2004. First Named Inventor, Timothy R. Conrad. Title, Airway Implant. |
File history of U.S. Appl. No. 11/757,501, now U.S. Pat. No. 7,703,460, as of Nov. 21, 2013, filed Jun. 4, 2007. First Named Inventor, Timothy R. Conrad. Title, Tongue Implant. |
File history of U.S. Appl. No. 12/214,084, as of Nov. 21, 2013, filed Jun. 17, 2008. First Named Inventor, Octavian Iancea. Title, Implantable devices, systems, and methods for maintaining desired orientations in targeted tissue regions. |
International Searching Authority, International Preliminary Report on Patentability, for International Application No. PCT/US2012/046923, dated Jan. 23, 2014, p. 1-7. |
Woodson et al. Multicenter study of a novel adjustable tongue-advacement device for obstructive sleep apnea [article]. Otolaryngology—head and neck surgery, vol. 143, No. 4, pp. 585-590. IP: 128.210.125.135. Jun. 10, 2010. SAGE. |
Woodson et al. Response to: Multicenter study of a novel adjustable tongue-advacement device for obstructive sleep apnea [article]. Otolaryngology—head and neck surgery, vol. 144, No. 6, pp. 1009-1012. 2011. SAGE. |
Siesta Medical. Siesta Medical receives 510(k) clearance for Encore system to treat obstructive sleep apnea [press release]. Sep. 12, 2011. pp. 1-2. |
Aspire Medical, Inc. Aspire Medical announces first implant in US and start of clinical trial to treat sleep apnea [article]. Medical News Today. May 23, 2007. pp. 1-4. URL: <http://www.medicalnewstoday.com/releases/71787.php>. |
Hamans et al. A novel tongue implant for tongue advancement for obstructive sleep apnea: feasibility, safety and histology in a canine model [article]. J Musculoskelet Neuronal Interact. vol. 10, No. 1, pp. 100-111. Dec. 29, 2009. Hylonome. |
Knobbe, Martens, Olson & Bear, LLP. Amendment and response to non-Final Office Action dated Jan. 16, 2013, for U.S. Appl. No. 13/077,813, filed Mar. 31, 2011. First Named Inventor, van der Burg. Title, Suture Passer Systems and Methods for Tongue or Other Tissue Suspension and Compression. |
PR Newswire. Asprie Medical appoints Roseanne Varner as president and CEO [press release]. pp. 1-2. May 1, 2011. URL: <http://www.prnewswire.com/news-releases/aspire-medical-appoints-roseanne-varner-as-president-and-ceo-57760852.html>. |
Park. Aspire Medical Advance System for obstructive sleep apnea [blog]. Dr. Park: Breathe better, sleep better, live better. pp. 1-4. Oct. 6, 2010. URL: <http://doctorstevenpark.com/aspire-medical-advance-system-for-obstructive-sleep-apnea>. |
Revent Medical. The Revent Solution: Tongue Implanter Kit [webpage]. 2014. pp. 1-2. Retrieved Aug. 12, 2014. URL: <http://www.reventmedical.com/solution/>. |
Revent Medical. The Revent Solution: Implants [webpage]. 2014. pp. 1-2. Retrieved Aug. 12, 2014. URL: <www.reventmedical.com/solution/>. |
European Patent Office, Examination Report for European Application No. 14752978.8; Mar. 31, 2017. |
Number | Date | Country | |
---|---|---|---|
20150034095 A1 | Feb 2015 | US |
Number | Date | Country | |
---|---|---|---|
61861089 | Aug 2013 | US |